Urologix, Inc. ULGX

Full chart Compare
Set alert

Price alert · ULGX

All alert types
0.00 USD 0.00 (+0.00%)

At closeNov 2, 2026, 4:00 PM EST

0.0001 Day range 0.0001
0.0001 52-week range 0.0126
YTD
0.00%
1 year
0.00%
Market cap
2.18K
Revenue (ttm)
12.00M
Profit margin
-38.90%
EPS (ttm)
-0.02
Shares out
21.28M
YTD return
0.00%
1-year return
0.00%
Volume
125
Avg volume
1.31K
Open
0.0001
Previous close
0.0001
Day's range
0.0001 – 0.0001
52-week range
0.0001 – 0.0126
Beta
5.55
Analysts
Strong Buy
Price target
1.50 (+1499900.0%)

3M 0.0000 (0.00%)

0.00010.00010.0001Aug 11Aug 28Sep 17Oct 6Oct 230.0001

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-16.70%
Free cash flow
725.88K
Total cash
492.00K
Total debt
5.33M
Return on equity
0.00%
Short % of float
0.30%
50-day average
0.001399
200-day average
0.00129

Financials — quick view

All financials
ULGX Revenue — quarterly 2.80M
2011-Q4 20112012-Q1 20112012-Q2 20112012-Q3 20122012-Q4 20122013-Q1 20122013-Q2 20122013-Q3 20132013-Q4 20132014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 2015
ULGX Net income — quarterly -349.00K
2011-Q4 20112012-Q1 20112012-Q2 20112012-Q3 20122012-Q4 20122013-Q1 20122013-Q2 20122013-Q3 20132013-Q4 20132014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 2015
ULGX EPS — quarterly -0.02
2011-Q4 20112012-Q1 20112012-Q2 20112012-Q3 20122012-Q4 20122013-Q1 20122013-Q2 20122013-Q3 20132013-Q4 20132014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 2015

Earnings

ULGX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 12, 2015Mar 1, 20150.00-0.02——
Feb 5, 2015Dec 1, 20140.00-0.02——

Upgrades / downgrades

ULGX analyst upgrades and downgrades
DateFirmActionFromTo
Jul 16, 2012Dougherty & Companyinit—Buy
Oct 28, 2007Feltl & Co.downBuyHold
Jul 17, 2007Feltl & Co.init—Buy
Apr 12, 2007CE Unterberg TowbindownMarket PerformUnderperform
Jan 25, 2007CE Unterberg TowbinupUnderperformMarket Perform
Aug 16, 2006CE Unterberg TowbindownMarket PerformUnderperform

About Urologix, Inc.

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy urethral tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate and destroys prostate tissue that reduces constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Medical Appliances & Equipment
Country
United States
Website
urologix.com

News

Your note

Sign in to keep a note on ULGX — it syncs with the Stock Master app.

Insider holders

ULGX insider holders
InsiderRelationLatest transactionDateShares held
MADSON SCOTT M.OfficerOwnership StatementMar 31, 20150